肺复康方治疗中晚期非小细胞肺癌30例

目的:观察中药肺复康方对中晚期非小细胞肺癌患者的生存期及原发病灶疗效的影响。方法:根据纳入标准选入60例中晚期非小细胞肺癌患者随机分为治疗组和对照组各30例。治疗组给予中药肺复康方治疗,对照组随访观察,对照统计两组半年、1年、2年生存率、中位生存期(MST)及原发病灶疗效。结果:治疗组的半年、1年、2年的生存率分别为63.33%、26.67%、6.67%,中位生存期为(6.000±0.782)个月;对照组的半年、1年、2年生存率分别为36.67%、10.00%、3.33%,中位生存期为(3.000±0.911)个月,治疗组的中位生存期较对照组延长了3个月。两组生存曲线比较,差异有统计学意义(P<0.05)。两组原发病灶的瘤体有效率和疾病控制率比较,治疗组分别是23.33%、83.33%,对照组是6.67%、30.00%,两组比较差异有显著性意义(P<0.05),治疗组优于对照组。结论:中药肺复康方治疗中晚期非小细胞肺癌可显著延长患者生存期,提高远期生存率,并且有效抑制瘤体增长。

Clinical Obervation on Feifukang in Treatment of 30 Cases of Advanced Non-Small Cell Lung Cancer

Objective: To observe the curative effect of Feifukang in the treatment of advanced non-small cell lung cancer patients' survival rate and the tumor size. Methods: 60 patients with advanced cancer were allocated to two groups randomly. The patients in treatment group were given pure traditional Chinese medicine Feifukang. The patients in control group were given symptomatic and supportive treatment. And then we counted the survival rate and primary lesion curative effect of two groups' patients.Results: Half,1-,2-year survival rates of the treatment group were 63. 33% 、26. 67% 、6. 67% and those of the control group were 36. 67%,10. 00% and 3. 33%,respectively. Median survival time of the treatment group was( 6. 000 ± 0. 782) months and the control group's was( 3. 000 ± 0. 911) months. The difference between two groups' survival curves was significant( P < 0. 05).Comparing the effect of the primary lesion and the disease control rates,the treatment group's were 23. 33% and 83. 33% and the control group's were 6. 67% and 30. 00%. And the different was significant( P < 0. 05). The effect of the treatment group was higher than that of the control group. Conclusion: Feifukang has favorable effects in extending survival time,improving the survival rate and stabilizing the tumor size.